COMPARE · Data as of August 21, 2026
ALNY vs EXEL
Verdict: Side-by-side breakdown using the Bull Rankings model. ALNY scored 75.0, EXEL scored 74.1 — ALNY leads.
Compare another set
ALNY
Alnylam Pharmaceuticals, Inc.
75
$232.12 · $31.1B
fundamentals as of
Score gap
0.9
ALNY leads
EXEL
Exelixis, Inc.
74.1
$54.14 · $13.4B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestEXEL17.0x
- Fastest growthALNY+65.2%
- Strongest balance sheetEXEL0.09
- Highest qualityEXEL97 / 100
- Largest discount to fair valueEXEL-42%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ALNY
stronger →← stronger
EXEL
67
Qualityreturns · margins · balance sheet
97
99
Growthrevenue & earnings expansion
80
64
Valuevaluation vs sector peers
53
ALNY is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ALNY
EXEL
$465mC
FCF
$1.2bC+
+65.2%A
Rev
+9.2%B
2.21D
D/E
0.09B+
40.4xC
P/E
17.0xA-
0.46A
PEG
2.56C
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ALNY
EXEL
184% above
Price vs fair valuelower is cheaper
42% below
~43%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-3%/yr
-73%
1-yr DCF upside
+45%
-65%
5-yr DCF upside
+71%
-47%
10-yr DCF upside
+118%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ALNY
Why this score
- Diluting shareholders
EXEL
Why this score
- Buying back stock
- Durable high returns
The companies
ALNYAlnylam Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $31.1b. Down 53% from 52-week high of $495.55 — deep drawdown territory. Revenue growing +65% — in hypergrowth territory. PEG 0.46 — paying under fair value for the growth rate. 26 sell-side analysts rate this a Buy with a mean 1-yr target of $370.20 (implying +59% upside).
Moat
Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 54% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.21 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 53% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 40x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
EXELExelixis, Inc.
Why now
Biotechnology · market cap $13.4b. 6% off the 52-week high of $57.57. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $53.00 (implying -2% upside).
Moat
Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 47% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 136% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ALNY and EXEL diverge
On the headline score the gap is 0.9 points in favor of ALNY. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- QualityALNY 66.8 · EXEL 96.8EXEL +30.0
- GrowthALNY 98.5 · EXEL 80.0ALNY +18.5
- ValueALNY 64.1 · EXEL 52.5ALNY +11.6
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.